Parathyroid Adenoma Detection With Rubidium-82 Imaging
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PET/CT imaging with rubidium-82.
- Who it may be relevant to
- Registry conditions: Parathyroid Adenomas, Hyperparathyroidism, Primary. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study
Overview
Assess the uptake of rubidium-82 in parathyroid adenomas.
Detailed description
Parathyroid adenomas demonstrate uptake of rubidium-82 chloride and can be detected with PET imaging.
The investigators aim to describe the uptake pattern of rubidium-82 chloride in parathyroid adenomas as well as compare the uptake pattern of rubidium-82 chloride to that of 18F-fluorocholine in patients with parathyroid adenoma.
Interventions
- Other PET/CT imaging with rubidium-82
PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.
Primary outcome measures
- Uptake pattern of rubidium-82 in parathyroid adenomas [Time frame: 3 months]
Secondary outcome measures (1)
- Comparison between the uptakes of rubidium-82 and 18F-fluorocholine in patients with parathyroid adenomas [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Age ≥ 18y
- Ability to undergo imaging logistics
- Ability to provide informed consent
- Biochemical evidence of primary hyperparathyroidism
- Documented parathyroid adenoma on prior 18F-fluorocholine imaging
Exclusion criteria
- Normocalcemic primary hyperparathyroidism
- Breastfeeding or pregnancy
- Claustrophobia or inability to undergo imaging logistics
- Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Canada · 2 centers
- Montreal Heart Institute — Montreal
- Montreal Jewish General Hospital — Montreal
Identifiers
NCT: NCT07099404 · MP-33-2025-3547